Supplementary Figure 4 from Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models

Míreanna comhchosúla

• Supplementary Figure 1 from Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models
  de réir: Shigehiro Yagishita (15088446)
  Foilsithe / Cruthaithe: (2025)
• Supplementary Figure 2 from Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models
  de réir: Shigehiro Yagishita (15088446)
  Foilsithe / Cruthaithe: (2025)
• Supplementary Figure 3 from Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models
  de réir: Shigehiro Yagishita (15088446)
  Foilsithe / Cruthaithe: (2025)
• Supplementary Data1 from Genomic Profiling in Patients with Endometrial Cancer by Deep Sequencing of Vaginal Swabs and Plasma
  de réir: Namsoo Kim (21718000)
  Foilsithe / Cruthaithe: (2025)
• Supplementary Table S4 from Evolution and Co-occurrence of PI3K Pathway Gene Mutations in Endometrial Carcinoma Molecular Subtypes at the Single-Cell Level
  de réir: Arnaud Da Cruz Paula (17316230)
  Foilsithe / Cruthaithe: (2025)